PT3565550T - Composições farmacêuticas compreendendo meloxicam e rizatriptano - Google Patents

Composições farmacêuticas compreendendo meloxicam e rizatriptano

Info

Publication number
PT3565550T
PT3565550T PT187362785T PT18736278T PT3565550T PT 3565550 T PT3565550 T PT 3565550T PT 187362785 T PT187362785 T PT 187362785T PT 18736278 T PT18736278 T PT 18736278T PT 3565550 T PT3565550 T PT 3565550T
Authority
PT
Portugal
Prior art keywords
meloxicam
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
PT187362785T
Other languages
English (en)
Original Assignee
Axsome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axsome Therapeutics Inc filed Critical Axsome Therapeutics Inc
Publication of PT3565550T publication Critical patent/PT3565550T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/485Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
PT187362785T 2017-01-04 2018-01-04 Composições farmacêuticas compreendendo meloxicam e rizatriptano PT3565550T (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762442136P 2017-01-04 2017-01-04
US201762504105P 2017-05-10 2017-05-10
US201762536466P 2017-07-25 2017-07-25

Publications (1)

Publication Number Publication Date
PT3565550T true PT3565550T (pt) 2021-01-20

Family

ID=62791365

Family Applications (1)

Application Number Title Priority Date Filing Date
PT187362785T PT3565550T (pt) 2017-01-04 2018-01-04 Composições farmacêuticas compreendendo meloxicam e rizatriptano

Country Status (20)

Country Link
US (4) US10137131B2 (pt)
EP (2) EP3565550B1 (pt)
JP (3) JP6870867B2 (pt)
KR (4) KR102627411B1 (pt)
CN (1) CN110621314A (pt)
AU (3) AU2018205790B2 (pt)
CA (2) CA3121746A1 (pt)
CO (1) CO2019008364A2 (pt)
CY (1) CY1123820T1 (pt)
DK (1) DK3565550T3 (pt)
ES (1) ES2845566T3 (pt)
HR (1) HRP20210034T1 (pt)
HU (1) HUE052749T2 (pt)
LT (1) LT3565550T (pt)
MX (2) MX2019008127A (pt)
PL (1) PL3565550T3 (pt)
PT (1) PT3565550T (pt)
RS (1) RS61346B1 (pt)
SI (1) SI3565550T1 (pt)
WO (1) WO2018129220A1 (pt)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10799588B2 (en) 2015-02-10 2020-10-13 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10537642B1 (en) 2015-02-10 2020-01-21 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10780165B2 (en) 2015-02-10 2020-09-22 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10512692B2 (en) 2015-02-10 2019-12-24 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10758618B2 (en) 2015-02-10 2020-09-01 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10780166B2 (en) 2015-02-10 2020-09-22 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10517950B1 (en) 2015-02-10 2019-12-31 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10933136B2 (en) 2015-02-10 2021-03-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729773B2 (en) 2015-02-10 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10821181B2 (en) 2015-02-10 2020-11-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10058614B2 (en) 2015-02-10 2018-08-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11602563B2 (en) 2015-02-10 2023-03-14 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11738085B2 (en) 2015-02-10 2023-08-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10702602B2 (en) 2015-02-10 2020-07-07 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10722583B2 (en) 2015-02-10 2020-07-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10933137B2 (en) 2015-02-10 2021-03-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729774B1 (en) 2015-02-10 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11110173B2 (en) 2015-02-10 2021-09-07 Axsome Therapeutics, Inc Pharmaceutical compositions comprising meloxicam
US11607456B2 (en) 2015-02-10 2023-03-21 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10695429B2 (en) 2015-02-10 2020-06-30 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10653777B2 (en) 2015-02-10 2020-05-19 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11013805B2 (en) 2015-02-10 2021-05-25 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11045549B2 (en) 2015-02-10 2021-06-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11013806B2 (en) 2015-02-10 2021-05-25 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10532101B1 (en) 2015-02-10 2020-01-14 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10695430B2 (en) 2015-02-10 2020-06-30 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11207327B2 (en) 2017-01-04 2021-12-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729697B2 (en) 2017-01-04 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11471465B2 (en) 2017-01-04 2022-10-18 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11801250B2 (en) 2017-01-04 2023-10-31 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10583088B2 (en) 2017-01-04 2020-03-10 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11266657B2 (en) 2017-01-04 2022-03-08 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10940153B2 (en) 2017-01-04 2021-03-09 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10905693B2 (en) 2017-01-04 2021-02-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11433078B2 (en) 2017-01-04 2022-09-06 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11617755B2 (en) 2017-01-04 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11806354B2 (en) 2017-01-04 2023-11-07 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
PL3565550T3 (pl) 2017-01-04 2021-07-19 Axsome Therapeutics, Inc. Kompozycje farmaceutyczne zawierające meloksykam i ryzatryptan
US11433079B2 (en) 2017-01-04 2022-09-06 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10583144B2 (en) 2017-01-04 2020-03-10 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10894053B2 (en) 2017-01-04 2021-01-19 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10561664B1 (en) 2017-01-04 2020-02-18 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10821182B2 (en) 2017-06-29 2020-11-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729696B2 (en) 2017-01-04 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10471014B2 (en) 2017-01-04 2019-11-12 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
JP6609071B2 (ja) * 2017-05-10 2019-11-20 アクスサム セラピューティクス インコーポレイテッド メロキシカムを含有する医薬組成物
US10512693B2 (en) 2017-06-29 2019-12-24 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11510927B2 (en) 2017-06-29 2022-11-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10918722B2 (en) 2017-06-29 2021-02-16 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11617791B2 (en) 2017-06-29 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11219626B2 (en) 2017-06-29 2022-01-11 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10688102B2 (en) 2017-06-29 2020-06-23 Axsome Therapeutics, Inc. Combination treatment for migraine and other pain
US11617756B2 (en) 2017-06-29 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11185550B2 (en) 2017-06-29 2021-11-30 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11865117B2 (en) 2017-06-29 2024-01-09 Axsome Therapeutics, Inc Pharmaceutical compositions comprising meloxicam
US10987358B2 (en) 2017-06-29 2021-04-27 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11712441B2 (en) 2017-06-29 2023-08-01 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10758617B2 (en) 2017-06-29 2020-09-01 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10688185B2 (en) 2017-06-29 2020-06-23 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11759522B2 (en) 2017-06-29 2023-09-19 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US20230285306A1 (en) * 2018-09-28 2023-09-14 Axsome Therapeutics, Inc. Dosage forms comprising active pharmaceutical ingredients
CN109111469A (zh) * 2018-10-09 2019-01-01 中国药科大学 一种含氯诺昔康的共无定形复合物
MA54904A (fr) * 2019-02-06 2021-12-15 Axsome Therapeutics Inc Compositions pharmaceutiques comprenant du méloxicam
KR20220164557A (ko) * 2020-04-06 2022-12-13 액섬 테라퓨틱스, 인크. 멜록시캄을 포함하는 제약 조성물
US20240058354A1 (en) * 2020-04-06 2024-02-22 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
WO2022122122A1 (en) 2020-12-08 2022-06-16 Symrise Ag Medicament for fighting inflammatory conditions of human skin (i)
JP2024502041A (ja) * 2020-12-31 2024-01-17 アクスサム セラピューティクス インコーポレイテッド メロキシカムを含む医薬組成物
US20230355637A1 (en) * 2020-12-31 2023-11-09 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284269A (en) 1993-06-28 1994-02-08 Petrie Jack G Space saving double seal
WO1996005199A1 (de) 1994-08-12 1996-02-22 Byk Gulden Lomberg Chemische Fabrik Gmbh Imidazopyridinsalz
WO1996005177A1 (en) 1994-08-13 1996-02-22 Yuhan Corporation Novel pyrimidine derivatives and processes for the preparation thereof
US8022095B2 (en) 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US6586458B1 (en) 1996-08-16 2003-07-01 Pozen Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US5872145A (en) 1996-08-16 1999-02-16 Pozen, Inc. Formulation of 5-HT agonist and NSAID for treatment of migraine
US6077539A (en) 1996-11-12 2000-06-20 Pozen, Inc. Treatment of migraine headache
KR100231723B1 (ko) 1996-12-28 1999-11-15 김영환 플래쉬 메모리 장치
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
WO1999009988A1 (en) * 1997-08-27 1999-03-04 Hexal Ag New pharmaceutical compositions of meloxicam with improved solubility and bioavailability
AU759307B2 (en) * 1998-11-02 2003-04-10 Merck Sharp & Dohme Corp. Method of treating migraines and pharmaceutical compositions
SE9804314D0 (sv) 1998-12-14 1998-12-14 Astra Ab New pharmaceutical formulation
DK1165044T3 (da) 1999-03-26 2004-10-25 Pozen Inc Höjpotente dihydroergotaminsammensætninger
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
EA006398B1 (ru) 2001-06-01 2005-12-29 Поузен Инк. Фармацевтические композиции для координированной доставки нестероидных противовоспалительных лекарственных средств
DK1575566T3 (da) 2002-12-26 2012-03-26 Pozen Inc Flerlagsdoseringsformer indeholdende naproxen og triptaner
US8512727B2 (en) 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
US20040214861A1 (en) * 2003-03-28 2004-10-28 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitors and 5-HT1B1D antagonists for the treatment and prevention of migraine
US20050249806A1 (en) 2004-02-10 2005-11-10 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory drug
US9016221B2 (en) 2004-02-17 2015-04-28 University Of Florida Research Foundation, Inc. Surface topographies for non-toxic bioadhesion control
WO2005105102A1 (en) 2004-05-04 2005-11-10 Equitech Corporation Improved nsaid composition
JP4617774B2 (ja) * 2004-08-26 2011-01-26 コニカミノルタホールディングス株式会社 カラートナー及びカラーフィルター
US20060105045A1 (en) * 2004-11-08 2006-05-18 Buchanan Charles M Cyclodextrin solubilizers for liquid and semi-solid formulations
US9265732B2 (en) 2006-03-06 2016-02-23 Pozen Inc. Dosage forms for administering combinations of drugs
US20070281927A1 (en) 2006-06-06 2007-12-06 Shanthakumar Tyavanagimatt Anti-inflammatory and analgesic compositions and related methods
WO2008006216A1 (en) 2006-07-14 2008-01-17 Mistral Pharma, Inc. Anti-inflammatory and cytoprotectant chronotherapy
JP2010507585A (ja) * 2006-10-19 2010-03-11 オースペックス・ファーマシューティカルズ・インコーポレイテッド 置換インドール
US20090068262A1 (en) * 2007-04-04 2009-03-12 Ilan Zalit Rapid dissolution of combination products
US8124603B2 (en) 2008-01-22 2012-02-28 Thar Pharmaceuticals In vivo studies of crystalline forms of meloxicam
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
AU2009290712A1 (en) 2008-09-09 2010-03-18 Astrazeneca Ab Method for delivering a pharmaceutical composition to patient in need thereof
HUE047755T2 (hu) 2009-05-13 2020-05-28 Cydex Pharmaceuticals Inc Prasugrelt és ciklodextrin-származékokat tartalmazó gyógyszerkészítmények, eljárás ezek elõállítására és alkalmazásra
EP2445499A4 (en) 2009-06-25 2013-02-27 Astrazeneca Ab METHOD FOR TREATING A PATIENT WITH RISK OF DEVELOPING A NSAID-ASSOCIATED SPURGE
CN101987081B (zh) 2010-07-16 2012-08-08 钟术光 一种控释制剂
DE102010052847A1 (de) 2010-11-29 2012-05-31 Temmler Werke Gmbh Verfahren zur Herstellung einer PPI-haltigen pharmazeutischen Zubereitung
CN102526058A (zh) 2010-12-28 2012-07-04 秦引林 一种含氯诺昔康和埃索美拉唑消炎镇痛药物组合物
CN104519888A (zh) 2011-12-28 2015-04-15 波曾公司 用于递送奥美拉唑和乙酰水杨酸的改良组合物和方法
WO2014161131A1 (en) 2013-04-01 2014-10-09 Arissa Pharma PREPARING AMORPHOUS MELOXICAM-β-CYCLODEXTRIN INCLUSION COMPLEX VIA SPRAY DRYING PROCESS
CA3000306A1 (en) 2014-09-29 2017-03-16 Hong Sun Compositions including meloxicam-cyclodextrin inclusion complexes and methods of treating acute pain
US10058614B2 (en) 2015-02-10 2018-08-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
KR102424013B1 (ko) * 2015-02-10 2022-07-25 액섬 테라퓨틱스, 인크. 멜록시캄을 포함하는 약학 조성물
US9821075B2 (en) * 2015-02-10 2017-11-21 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10583088B2 (en) 2017-01-04 2020-03-10 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10471014B2 (en) 2017-01-04 2019-11-12 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
PL3565550T3 (pl) 2017-01-04 2021-07-19 Axsome Therapeutics, Inc. Kompozycje farmaceutyczne zawierające meloksykam i ryzatryptan
KR102209773B1 (ko) * 2017-05-29 2021-01-28 주식회사 엘지화학 배터리 모듈

Also Published As

Publication number Publication date
EP3789016A1 (en) 2021-03-10
CY1123820T1 (el) 2022-05-27
HUE052749T2 (hu) 2021-12-28
KR20230017366A (ko) 2023-02-03
KR20190122659A (ko) 2019-10-30
MX2021014509A (es) 2022-01-06
NZ755129A (en) 2021-10-29
KR102627411B1 (ko) 2024-01-18
CN110621314A (zh) 2019-12-27
US20190070192A1 (en) 2019-03-07
PL3565550T3 (pl) 2021-07-19
US20190231792A1 (en) 2019-08-01
KR20240013848A (ko) 2024-01-30
US10471069B2 (en) 2019-11-12
AU2018205790B2 (en) 2020-07-09
RS61346B1 (sr) 2021-02-26
SI3565550T1 (sl) 2021-04-30
JP2021107413A (ja) 2021-07-29
CA3121746A1 (en) 2018-07-12
AU2020244610B2 (en) 2021-11-04
AU2020244610A1 (en) 2021-01-21
US20180256593A1 (en) 2018-09-13
EP3565550A1 (en) 2019-11-13
KR20210107157A (ko) 2021-08-31
MX2019008127A (es) 2019-12-02
ES2845566T3 (es) 2021-07-27
US10265324B2 (en) 2019-04-23
HRP20210034T1 (hr) 2021-04-02
US20180214380A1 (en) 2018-08-02
EP3565550A4 (en) 2020-01-22
KR102493541B1 (ko) 2023-01-30
LT3565550T (lt) 2021-03-25
JP2020503360A (ja) 2020-01-30
WO2018129220A1 (en) 2018-07-12
DK3565550T3 (da) 2021-01-18
CA3049229C (en) 2021-07-27
EP3565550B1 (en) 2020-10-28
AU2022200590A1 (en) 2022-03-17
JP2023144095A (ja) 2023-10-06
CO2019008364A2 (es) 2019-08-20
AU2018205790A1 (en) 2019-07-25
BR112019013901A2 (pt) 2020-02-04
JP6870867B2 (ja) 2021-05-12
CA3049229A1 (en) 2018-07-12
US10137131B2 (en) 2018-11-27
US10471068B2 (en) 2019-11-12

Similar Documents

Publication Publication Date Title
IL281863A (en) Preparations containing meloxicam
PT3565550T (pt) Composições farmacêuticas compreendendo meloxicam e rizatriptano
IL279442A (en) Pharmaceutical preparations that include meloxicam
IL271657A (en) medical preparation
EP3621621A4 (en) PHARMACEUTICAL COMPOSITIONS WITH MELOXICAM
IL269061A (en) A pharmaceutical preparation containing Selexifag
IL271986A (en) pharmaceutical preparation
IL271759A (en) Pharmaceutical preparations that include anthraxtinib
GB201712159D0 (en) Pharmaceutical composition
GB201705303D0 (en) Pharmaceutical compositions
SG11202001179YA (en) Pharmaceutical compositions
GB201719447D0 (en) Pharmaceutical composition
IL272419A (en) Pharmaceutical composition
GB201705305D0 (en) Pharmaceutical compositions
GB201705304D0 (en) Pharmaceutical compositions
GB201705306D0 (en) Pharmaceutical compositions
EP3727485C0 (en) PHARMACEUTICAL COMPOSITION
HK1243650A1 (zh) 包含美洛昔康的藥物組合物
IL272044A (en) Pharmacy preparations
IL272428A (en) pharmaceutical preparations
ZA202000014B (en) Pharmaceutical compositions
GB201715404D0 (en) Pharmaceutical compositions
GB201715881D0 (en) New pharmaceutical compositions
GB201710114D0 (en) Pharmaceutical compositions
HRP20220610T8 (hr) Farmaceutski pripravci koji sadrže meloksikam